MISSISSAUGA, Ontario– Bayer Canada has entered into a new distribution partnership with Mint Pharmaceuticals Inc. for ADALAT XL (nifedipine extended-release tablets) 30 mg. The collaboration, which took effect on September 3, 2025, is intended to strengthen access to the widely used therapy across Canada.
ADALAT XL first received market authorization in Canada in 1995 and is indicated for the management of chronic stable angina as well as mild to moderate essential hypertension. Bayer said the new agreement with Mint will help ensure the product remains readily available to Canadian patients who rely on it.
“We are excited to partner with Mint Pharmaceuticals Inc., a company known for its commitment to quality and customer service,” said Viktoria Friedrich, Country President and General Manager of Bayer Inc.’s Pharmaceutical Division. “This partnership will enable us to leverage Mint’s extensive distribution network and expertise in the Canadian market, ensuring that ADALAT XL remains readily available to those who need it.”
Jaiveer Singh, Chief Executive Officer of Mint Pharmaceuticals, said the partnership underscores both companies’ shared focus on reliability and patient care. “Canadian patients and healthcare professionals depend on uninterrupted access to vital medicines, and that responsibility drives everything we do at Mint,” Singh said. “By partnering with Bayer, we are reinforcing our shared commitment to reliability, quality, and patient care. With a best-in-class supply chain built over the past 15 years, Mint is proud to bring that strength to the distribution of ADALAT XL, ensuring Canadians have seamless access to this trusted therapy.”
Bayer and Mint emphasized that the collaboration is focused on maintaining the highest standards of distribution so that healthcare providers and patients can continue to rely on the timely availability of ADALAT XL.
